Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)
Oncology2004Vol. 66(4), pp. 303–309
Citations Over TimeTop 17% of 2004 papers
Robert Shepard, Donna E. Levy, Jordan Berlin, Keith Stuart, Jules E. Harris, V. Avilés, James P. Thomas, Al B. Benson
Abstract
The confirmed complete response rate of 6% and partial response rate of 6% is encouraging, but the toxicity of this regimen appears significant. Based upon these results, this combination of gemcitabine and docetaxel is not worthy of further study. Different schedules and dosages may be more promising.
Related Papers
- → Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer(2013)34 cited
- → Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer(2014)13 cited
- → Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey(2015)4 cited
- → Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer(2007)6 cited
- → 1147 Gemcitabine in resistant stage IV bladder cancer: A phase II study(1995)2 cited